HomeNYSE:BMY

NYSE:BMY

Bristol Myers to Acquire Karuna Therapeutics for $14 Billion

Bristol Myers to Acquire Karuna Therapeutics for $14 Billion

December 22, 2023

Bristol-Myers Reports Disappointing Q2 Earnings and Sales

Bristol-Myers Reports Disappointing Q2 Earnings and Sales

July 27, 2023

Bmy Stock Rises as Trials for MS Drug Zeposia Record Serologic Response to COVID Vaccines Among Recipients

Bmy Stock Rises as Trials for MS Drug Zeposia Record Serologic Response to COVID Vaccines Among Recipients

October 26, 2022

Bristol Myers’ Q3 Revenues Decreased Due to Generic Revlimid Competition and Currency Issues

Bristol Myers’ Q3 Revenues Decreased Due to Generic Revlimid Competition and Currency Issues

October 26, 2022

Bristol Stock Has Signed an Agreement With the Small Company Synthex to Work Together on Selective Protein Cleavers.

Bristol Stock Has Signed an Agreement With the Small Company Synthex to Work Together on Selective Protein Cleavers.

October 4, 2022

Bristol Myers Squibb stock and SPPI increase on FDA approvals, CLVS increases by 15%, and TWTR decreases on the Musk saga

Bristol Myers Squibb stock and SPPI increase on FDA approvals, CLVS increases by 15%, and TWTR decreases on the Musk saga

September 14, 2022

BMY Stock and SPPI Increase on FDA Approvals, CLVS Increases by 15%, and Twtr Decreases on the Musk Saga

BMY Stock and SPPI Increase on FDA Approvals, CLVS Increases by 15%, and Twtr Decreases on the Musk Saga

September 12, 2022

Bristol-Myers Slumps 5% Largest Drop In 2 Years Following Mid-Stage Data for Blood Thinner

Bristol-Myers Slumps 5% Largest Drop In 2 Years Following Mid-Stage Data for Blood Thinner

August 29, 2022